Stock Events

Enlivex Therapeutics 

€1.25
2
+€0+0% Today

Statistics

Day High
1.25
Day Low
1.25
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
25.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

24JunExpected
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.54
-0.36
-0.18
0
Expected EPS
-0.21
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1BT.F. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap825.51M
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Enlivex's cell therapy approach for inflammatory conditions.
Fate Therapeutics
FATE
Mkt Cap486.06M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, directly competing with Enlivex's immunotherapy treatments.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics is a gene editing company that competes in the broader field of genetic and cell therapies, potentially targeting similar diseases as Enlivex.
Novartis
NVS
Mkt Cap232.42B
Novartis AG, through its advanced cell therapy platforms, competes in developing treatments for inflammatory and autoimmune diseases, similar to Enlivex's focus areas.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, with its cell therapy and immunology portfolio, competes in the same therapeutic areas as Enlivex, particularly in treatments for inflammatory and autoimmune diseases.
Bluebird bio
BLUE
Mkt Cap114.8M
Bluebird bio focuses on gene therapies for severe genetic diseases and cancer, competing with Enlivex's approach to treating severe medical conditions through advanced therapies.
Allogene Therapeutics
ALLO
Mkt Cap591.47M
Allogene Therapeutics is developing allogeneic CAR T cell therapies, which could compete with Enlivex's cell-based therapies for cancer and immune disorders.
Sangamo Therapeutics
SGMO
Mkt Cap82.4M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the innovative treatment space alongside Enlivex.
Adaptimmune Therapeutics
ADAP
Mkt Cap180.95M
Adaptimmune Therapeutics works on T-cell therapy to treat cancer, directly competing with Enlivex's immunotherapeutic approaches for oncology.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.97B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with Enlivex's focus on severe and life-threatening conditions.

About

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Show more...
CEO
Mr. Shai Novik M.B.A.
Country
IL
ISIN
IL0011319527
WKN
000A119KH

Listings

XNAS
US
ENLV
TA
IL
ENLV.TA
F
DE
1BT.F